MedPath

CTX130

Generic Name
CTX130
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.

Associated Conditions
-
Associated Therapies
-

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Phase 1
Terminated
Conditions
T Cell Lymphoma
Interventions
First Posted Date
2020-08-06
Last Posted Date
2025-01-08
Lead Sponsor
CRISPR Therapeutics AG
Target Recruit Count
49
Registration Number
NCT04502446
Locations
🇺🇸

Research Site 9, New York, New York, United States

🇺🇸

Research Site 1, Houston, Texas, United States

🇨🇦

Research Site 7, Toronto, Ontario, Canada

and more 7 locations

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Phase 1
Terminated
Conditions
Renal Cell Carcinoma
Interventions
First Posted Date
2020-06-18
Last Posted Date
2025-01-08
Lead Sponsor
CRISPR Therapeutics AG
Target Recruit Count
19
Registration Number
NCT04438083
Locations
🇺🇸

Research Site 2, Duarte, California, United States

🇦🇺

Research Site 1, Melbourne, Victoria, Australia

🇳🇱

Research Site 7, Amsterdam, North Holland, Netherlands

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath